You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic
  1. Alireza Khabbazi,
  2. Hadiseh Kavandi,
  3. Roghayeh Paribanaem,
  4. Raha Khabbazi,
  5. Aida Malek Mahdavi
  1. Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  1. Correspondence to Dr Aida Malek Mahdavi, Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz 5166614756, Iran; aidamalek{at}gmail.com

https://doi.org/10.1136/annrheumdis-2020-218756

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    With great interest, we read the Pineda-Sic et al’s report on treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic in Latin America.1 They reported that 15.1% of patients with rheumatic disease suspend their medications during COVID-19 crisis.1 Lack of availability (48%) and fear of the immunosuppressive effect of medications (25%) were the most common reasons. To address medication non-adherence in our population, we conducted a study about medication adherence in patients with rheumatic diseases in the East Azarbaijan province, which is one of the provinces of Iran with a high prevalence of COVID-19. The study was conducted in accordance with the Helsinki humanity research declaration (2008). For a period of 2 weeks from 10 to 24 July 2020, information about adherence to medication behaviours of patients after COVID-19 outbreak was obtained by telephone interview in patients with various rheumatic diseases treated …

    View Full Text

    Linked Articles